Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLINTON’s NIH TRANSITION TEAM MEMBERS ARE CAPITOL HILL STAFFER STEVE MORIN, MEDICINE SCHOOL DEAN JORDAN COHEN, BIOTECH ATTORNEY THOMAS SPARKS

Executive Summary

A Capitol Hill staffer with extensive AIDS policy experience is one of three transition officials chosen to evaluate key NIH policy issues requiring attention within the first 90 to 180 days of the incoming Clinton administration. Steve Morin, a member of Rep. Nancy Pelosi's (D-Calif.) staff, heads the transition team's AIDS cluster group. He is joined by Jordan Cohen, dean of the School of Medicine at the State University of New York at Stonybrook, and Thomas Sparks, an attorney specializing in biotechnology, securities and venture capital issues with the San Francisco firm of Pillsbury, Madison & Sutro. The three-member NIH group is part of a nine-member team that fanned out across the Public Health Service to conduct interviews with top officials, agency heads and institute directors during the first two weeks of December. NIH issues highlighted during the discussions include the NIH strategic plan, fetal tissue transplantation research and ongoing, as well as planned, research on violence prevention. An NIH briefing document prepared by Morin, Cohen and Sparks is being submitted to President-elect Clinton and to HHS Secretary- designate Donna Shalala. Other members of the PHS transition team are: John Jonas, of the Washington, D.C. law firm of Patton, Boggs & Blow; Linda Randolph, a professor in the Department of Community Medicine at New York's Mt. Sinai Medical Center, and former public health director with the New York State Department of Health; Myra Snyder, San Francisco deputy mayor for Health and Human Services; Phyllis Greenberger, Associate Director of Governmental Relations at the American Psychiatric Association; David Jackson, president of AssurQual, a medical consulting and software firm, and former director of the Ohio Department of Health; and Ronald Weich, chief counsel for the Senate Labor and Human Resources Committee. The PHS team is directed by William Corr, staff director and chief counsel for the Senate Judiciary/Antitrust Subcommittee ("The Pink Sheet" Dec. 14, p. 3). The PHS group reports to an HHS team that includes New Jersey Office of Management and Planning Chief of Staff Brenda Bacon. Former Rep. Thomas Downey (D-N.Y.) is charged with coordinating audits of HHS, the Department of Veterans Affairs and the Department of Housing and Urban Development for the incoming administration ("The Pink Sheet" Nov. 30, p. 5). In preparing its briefing document, the PHS transition group drew upon the work of PHS staff, which developed a separate analysis of the agency's mission, organization and programs. Coordinated by HHS Deputy Assistant Secretary for Health Planning and Evaluation James Friedman and completed during the week of Dec. 7, the document includes a section on PHS agency mission statements, short biographies on current institute and bureau directors, and a section that summarizes cross-cutting policy issues, AIDS and "Healthy People 2000" objectives. In its evaluation of NIH, the PHS document examines current policy on fetal tissue transplantation research; patenting of cDNA sequences; conflict of interest regulations now being developed; the NIH strategic plan; technology transfer; the "reasonable pricing" clause included in joint private/public Cooperative Research and Development Agreements; and indirect research cost revisions. In addition to providing an overview of current federal AIDS services, prevention and research efforts, the AIDS section discusses the Centers for Disease Control and Prevention's AIDS surveillance case definition, the National Commission on AIDS, current immigration policy on HIV-positive individuals, and AIDS vaccine liability as it relates to clinical trials. Other issues featured in the PHS staff analysis include minority health and women's health programs and policies, violence prevention research, risk assessment, adolescent health, mammogram legislation, emergency preparedness and the pending Senior Biomedical Research Service reorganization.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel